Background
Zielinski is the son of the writer Adam Zielinski and his wife Sophie.
oncologist physician university professor
Zielinski is the son of the writer Adam Zielinski and his wife Sophie.
In 1957 he came with his parents to Vienna, where he finished schooling in 1970. He studied medicine at Medical University of Vienna and received his Doctor of Medicine degree in 1976.
A medical oncologist, Zielinski is Director of the Clinical Division of Oncology and Chairman of the Department of Medicine I and the Comprehensive Cancer Centre at the Medical University of Vienna. Apart from two years as a fellow at the Cancer Research Center at Tufts University his career has been spent at Medical University of Vienna. He became Professor of Medical Experimental Oncology in 1992, Chairman of the Clinical Division of Oncology in 2002 and Director of the Department of Medicine I in 2004.
Contributions to medical knowledge
Zielinski"s research focuses on clinical trials in breast and lung cancer as well as personalised medicine and immuno-oncology.
As at late 2015 he had published more than 600 papers. Work as editor
ESMO announced in September 2015 that Zielinski would be Editor-in-Chief of ESMO Open, the Society"s new peer-reviewed, open-access, online-only journal.
Work as adviser
In January 2014 Zielinski joined the Scientific Advisory Board of the biotechnology company Imugene, whose lead product is a B cell peptide cancer immunotherapy which was developed at Medical University of Vienna in the laboratory of Professor Ursula Wiedermann.
2003: Anton-Gindely Prize, recognising Zielinski"s work as President of the Central European Cooperative Oncology Group 2003: City of Vienna Prize for Medical Sciences 2013: Honorary degree by Titu Maiorescu University in Bucharest 2014: Grand Decoration of Honour in Silver for Services to the Republic of Austria.
Outside his work in Vienna, Zielinski was named President of the Central European Cooperative Oncology Group since 1999 and became a member of the Executive Board of the European Society for Medical Oncology (ESMO) in 2014.